529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Susana Banerjee, M. Imbimbo, P. Roxburgh, JW Kim, Myoung Hwa Kim, R. Plummer, S. Stemmer, B. You, M. Ferguson, R.T. Penson, D. O'Malley, K. Meyer, H. Gao, H. Angell, Ana T. Nunes, S. Domchek, Y. Drew
Topics & Concepts
MedicineOlaparibBevacizumabOncologyGermlineOvarian cancerInternal medicineBRCA mutationDurvalumabGynecologyCancerChemotherapyPoly ADP ribose polymeraseNivolumabGeneticsImmunotherapyGenePolymeraseBiologyPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer